⌘K
t
N4 Pharma Plc announced on 15 July 2022 an update on its pre-clinical study with TNF alpha. The company reported that a Medicines Discovery Catapult study, previously updated on 13 June 2022, showed clear tumour suppression with 10ug of TNF-alpha loaded onto Nuvec®. Completed biochemical analysis confirmed increased circulating plasma TNF-alpha levels and indicated liver and tumour cells may have been responsible for transfection and subsequent TNF-alpha release.
| Date | 15 Jul 2022 |
| Time | 07:00:04 |
| Category | Corporate updates |
| ID | 5599S |
|
|
|
15 July 2022
N4 Pharma Plc
("N4 Pharma" or the "Company")
Work Programme Update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce a further update on its recent pre-clinical study with TNF alpha.
On 13 June 2022 the Company provided an update that the Medicines Discovery Catapult study showed clear tumour suppression with 10ug of the TNF-alpha loaded onto Nuvec® which was a lower dose than used in the earlier studies.
Biochemical analysis of blood and tissue samples has now been completed. Testing confirmed that treatment with 10ug TNF-alpha loaded onto Nuvec® resulted in an increase in circulating plasma TNF-alpha levels.
Analysis also indicated that tissues including the liver and the tumour cells may have been responsible for the transfection with the TNF plasmid and subsequent release of TNF-alpha into the circulation to suppress the tumour.
This study provides further data to better understand the mechanism that produced the tumour suppression. This data indicates the most appropriate use of Nuvec® in the oncology field will likely be to combine it with one or more nucleic acids alongside a targeting ligand to allow specific cancer cells to be targeted.
The posters resulting from the original oncology studies undertaken by Nanomerics have been presented at the CRS Annual Meeting in Montreal, Canada and are available to view on the Company's website.
Nigel Theobald, Chief Executive Officer of the Company, commented:
"We continue to make good progress in understanding how Nuvec® can be used in the oncology space and this work, combined with the potential opening up of the siRNA market and the early data coming from UQ on their oral work, gives us a lot of material to further focus our route to commercial success.
"We will provide a further update of this along with our interim results."
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 which has been incorporated into UK law by the European Union (Withdrawal) Act 2018.
Enquiries:
|
N4 Pharma Plc Nigel Theobald, CEO Luke Cairns, Executive Director |
Via IFC Advisory |
|
|
|
|
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe (Corporate Finance) Vadim Alexandre/Rob Rees (Corporate Broking) |
Tel: +44 (0)20 3470 0470 |
|
|
|
|
IFC Advisory Limited Financial PR Graham Herring Zach Cohen |
Tel: +44 (0)20 3934 6630 |
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.